PMID- 28754600
OWN - NLM
STAT- MEDLINE
DCOM- 20180219
LR  - 20181202
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 19
IP  - 9
DP  - 2017 Sep
TI  - Building blocks for institutional preparation of CTL019 delivery.
PG  - 1015-1024
LID - S1465-3249(17)30600-X [pii]
LID - 10.1016/j.jcyt.2017.06.001 [doi]
AB  - Chimeric antigen receptor (CAR) T-cell therapy is an investigational 
      immunocellular therapy that reprograms a patient's cytotoxic T cells to engage 
      and eliminate malignant cells. CAR T-cell therapies targeting the CD19 antigen 
      have demonstrated high efficacy in clinical trials for patients with B-cell 
      malignancies and may potentially be available on a broader scale in the future. 
      CAR T-cell therapy begins with the collection of a sufficient number of T cells 
      from a patient's peripheral blood through leukapheresis. Several factors must be 
      considered when patients undergo leukapheresis for CAR T-cell therapy, including 
      age and prior therapies. The leukapheresis material is shipped to a manufacturing 
      facility, followed by return of the CAR T cells to the treatment center. Careful 
      coordination of a multidisciplinary team composed of physicians, nurses, 
      pharmacists and other hospital personnel is critical for the proper care of the 
      patient before, during and after CAR T-cell therapy. CAR T-cell therapy has been 
      associated with adverse events (AEs) such as cytokine release syndrome, which 
      requires rapid attention by the emergency department, intensive care unit and 
      hospital pharmacy. In this review, we discuss several aspects of institutional 
      preparation for leukapheresis, CAR T-cell infusion and AE management based on our 
      experience with clinical trials of the CD19 CAR T-cell therapy CTL019.
CI  - Copyright (c) 2017 International Society for Cellular Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - McGuirk, Joseph
AU  - McGuirk J
AD  - The University of Kansas Medical Center, Kansas City, KS, USA. Electronic 
      address: jmcguirk@kumc.edu.
FAU - Waller, Edmund K
AU  - Waller EK
AD  - Emory University School of Medicine, Atlanta, GA, USA.
FAU - Qayed, Muna
AU  - Qayed M
AD  - Emory University School of Medicine, Atlanta, GA, USA.
FAU - Abhyankar, Sunil
AU  - Abhyankar S
AD  - The University of Kansas Medical Center, Kansas City, KS, USA.
FAU - Ericson, Solveig
AU  - Ericson S
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
FAU - Holman, Peter
AU  - Holman P
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
FAU - Keir, Christopher
AU  - Keir C
AD  - Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
FAU - Myers, G Douglas
AU  - Myers GD
AD  - University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
LA  - eng
GR  - UL1 TR000454/TR/NCATS NIH HHS/United States
GR  - KL2 TR000455/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170725
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Antigens, CD19)
RN  - 0 (CTL019 chimeric antigen receptor)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Antigens, CD19/immunology
MH  - B-Lymphocytes/pathology
MH  - Cell Transplantation/*methods
MH  - Cell- and Tissue-Based Therapy
MH  - Clinical Trials as Topic
MH  - Hematologic Neoplasms/*therapy
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Leukapheresis/*methods
MH  - Pharmacy Service, Hospital
MH  - Receptors, Antigen, T-Cell/*administration & dosage/genetics/immunology
MH  - Recombinant Proteins/administration & dosage/genetics/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
OTO - NOTNLM
OT  - blood component removal
OT  - clinical trial
OT  - genetic therapy
OT  - leukapheresis
EDAT- 2017/07/30 06:00
MHDA- 2018/02/20 06:00
CRDT- 2017/07/30 06:00
PHST- 2017/03/16 00:00 [received]
PHST- 2017/05/31 00:00 [revised]
PHST- 2017/06/02 00:00 [accepted]
PHST- 2017/07/30 06:00 [pubmed]
PHST- 2018/02/20 06:00 [medline]
PHST- 2017/07/30 06:00 [entrez]
AID - S1465-3249(17)30600-X [pii]
AID - 10.1016/j.jcyt.2017.06.001 [doi]
PST - ppublish
SO  - Cytotherapy. 2017 Sep;19(9):1015-1024. doi: 10.1016/j.jcyt.2017.06.001. Epub 2017 
      Jul 25.